Leekha, Ankita
Saeedi, Arash
Kumar, Monish
Sefat, K. M. Samiur Rahman
Martinez-Paniagua, Melisa
Meng, Hui
Fathi, Mohsen
Kulkarni, Rohan
Reichel, Kate
Biswas, Sujit
Tsitoura, Daphne
Liu, Xinli
Cooper, Laurence J. N.
Sands, Courtney M.
Das, Vallabh E.
Sebastian, Manu
Hurst, Brett L. http://orcid.org/0000-0003-1025-5878
Varadarajan, Navin http://orcid.org/0000-0001-7524-8228
Article History
Received: 10 November 2022
Accepted: 4 July 2024
First Online: 18 July 2024
Competing interests
: UH has filed provisional patents based on the findings of this study. N.V. and L.J.N.C. are co-founders of AuraVax Therapeutics and CellChorus. The remaining authors declare no competing interests.
: The mouse, hamster, and NHP studies were performed under the study protocol (PROTO2020000019, PROTO202100006, PROTO202100049, PROTO202200025), as approved by the Institutional Animal Care and Use Committee in the University of Houston. The animal experiments at USU were conducted in accordance with an approved protocol by the Institutional Animal Care and Use Committee of Utah State University. The work was performed in the AAALAC-accredited LARC of the university in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (8th edition; 2011).